PMID- 37625215
OWN - NLM
STAT- MEDLINE
DCOM- 20231120
LR  - 20231121
IS  - 2210-7762 (Print)
VI  - 278-279
DP  - 2023 Nov
TI  - Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization 
      (FISH) as prognostic factors in malignant glioma patients on treatment with 
      alkylating chemotherapy.
PG  - 55-61
LID - S2210-7762(23)00054-6 [pii]
LID - 10.1016/j.cancergen.2023.08.005 [doi]
AB  - BACKGROUND: Either deletion or co-deletion of chromosomal arms 1p or 19q is a 
      characteristic and early genetic event in oligodendroglial tumors that is 
      associated with a better prognosis and enhanced response to therapy. Information 
      of 1p/19q status is now regarded as the standard of care when managing 
      oligodendroglial tumors for therapeutic options in anticipation of the increased 
      survival and progression-free survival times associated with it. Keeping this in 
      view, we first time attempted to establish the FISH based detection of 1p/19q 
      deletion in glioma tissue samples to evaluate its role and involvement in the 
      disease. METHOD: Overall 39 glioma cases of different histologies were evaluated 
      by fluorescence in situ hybridization (FISH) technique using specific FISH probes 
      with Olympus BX43 fluorescent microscope to detect chromosomes 1p and 19q or 
      co-deletions therein. RESULTS: Of the 39 glioma samples, overall 27 (69.2%) were 
      found to have deletion either in 1p, 19q or both. Deletions were observed in 
      23.0%, 7.6% and 38.4% in 1p, 19q and 1p/19q co-deletions respectively. Overall 
      oligidendrioglioma presented with 53.8% (21 of 39) deletions, astrocytoma group 
      showed 12.8% and GBM accounted for 2.5% deletions. Overall survival and disease 
      free survival was seen significantly better in oligidendrioglioma and astrocytoma 
      with deleted tumors as compared to non-deleted ones (p<0.05). CONCLUSION: Allelic 
      losses on 1p and 19q, either discretely or shared, were more frequent in classic 
      oligodendrogliomas than in either astrocytoma or Glioblastoma with better 
      survival and response to therapy.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Pandith, Arshad A
AU  - Pandith AA
AD  - Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J & K, India. Electronic address: arshad.pandith@skims.ac.in.
FAU - Zahoor, Wani
AU  - Zahoor W
AD  - Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J & K, India.
FAU - Manzoor, Usma
AU  - Manzoor U
AD  - Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J & K, India.
FAU - Nisar, Syed
AU  - Nisar S
AD  - Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J&K, India.
FAU - Guru, Faisal R
AU  - Guru FR
AD  - Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J&K, India.
FAU - Naikoo, Niyaz A
AU  - Naikoo NA
AD  - Department of Biotechnology, Higher Education Department, Cluster University, 
      Srinagar, J & K, India.
FAU - Aein, Qurat Ul
AU  - Aein QU
AD  - Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J & K, India.
FAU - Baba, Shahid M
AU  - Baba SM
AD  - Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences 
      (SKIMS), Srinagar, J & K, India.
FAU - Bhat, Abdul R
AU  - Bhat AR
AD  - Department of Neurosurgery, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), 
      Srinagar, J&K, India.
FAU - Ganai, Farooq
AU  - Ganai F
AD  - Department of CVTS, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), 
      Srinagar, J&K, India.
FAU - Shah, Parveen
AU  - Shah P
AD  - Department of Pathology, SKIMS, Srinagar, J & K, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230810
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - In Situ Hybridization, Fluorescence
MH  - *Brain Neoplasms/drug therapy/genetics/pathology
MH  - Chromosome Deletion
MH  - *Glioma/drug therapy/genetics/pathology
MH  - *Oligodendroglioma/drug therapy/genetics/pathology
MH  - *Astrocytoma/genetics
MH  - Chromosome Aberrations
MH  - Chromosomes
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Chromosomes, Human, Pair 19/genetics
OTO - NOTNLM
OT  - Astrocytoma
OT  - Chromosome 1p/19q
OT  - Co-deletion
OT  - Glioblastoma
OT  - Glioma
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/26 05:42
MHDA- 2023/11/20 06:54
CRDT- 2023/08/25 18:02
PHST- 2023/04/07 00:00 [received]
PHST- 2023/07/12 00:00 [revised]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/11/20 06:54 [medline]
PHST- 2023/08/26 05:42 [pubmed]
PHST- 2023/08/25 18:02 [entrez]
AID - S2210-7762(23)00054-6 [pii]
AID - 10.1016/j.cancergen.2023.08.005 [doi]
PST - ppublish
SO  - Cancer Genet. 2023 Nov;278-279:55-61. doi: 10.1016/j.cancergen.2023.08.005. Epub 
      2023 Aug 10.